학술논문
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study
Document Type
article
Author
Alexandra Rezazadeh; Aniko Szabo; Arushi Khurana; David J. Inwards; Matthew A. Lunning; Nancy L. Bartlett; Paolo F. Caimi; Thomas D. Rodgers; Paul M. Barr; Sayan Mullick Chowdhury; Narendranath Epperla; Hiruni Mendries; Brian T. Hill; Timothy S. Oh; Reem Karmali; Julie E. Chang; Gaurav Goyal; Benjamin M. Parsons; Krista M. Isaac; Craig A. Portell; Kathleen Monahan; Malika Siker; David M. King; Timothy S. Fenske
Source
Haematologica, Vol 109, Iss 5 (2023)
Subject
Language
English
ISSN
0390-6078
1592-8721
1592-8721
Abstract
Primary bone diffuse large B-cell lymphoma is a rare variant of extranodal non-Hodgkin lymphoma historically treated with induction chemotherapy followed by consolidative radiation therapy (RT). It remains unknown whether RT confers additional benefit following rituximab-based chemoimmunotherapy (CIT) induction in patients with limited stage disease. We conducted a multicenter, retrospective analysis of patients treated between 2005 and 2019 using rituximab-based CIT regimens with or without consolidative RT to discern whether consolidative RT adds benefit in patients with stage I-II disease that could be encompassed in one radiation field. A total of 112 patients were included: 78 received CIT and radiation (RT group), and 34 received CIT alone (no RT group). The overall survival at 10 years was 77.9% in the RT group and 89.0% in the no RT group (P=0.42). The relapse-free survival at 10 years was 73.5% in the RT group and 80.3% in the no RT group (P=0.88). Neither improved overall survival nor relapse-free survival was associated with the addition of consolidative RT. Subgroup analysis of patients only achieving a partial response after CIT suggests that these patients may benefit from consolidative RT.